OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
GNPX Genprex
- 0.2453
- -0.0258-9.52%
Close Mar 31 16:00 ET
- 0.2425
- -0.0028-1.14%
Pre 06:46 ET
2.09MMarket Cap-0.02P/E (TTM)
0.2635High0.2300Low1.89MVolume0.2635Open0.2711Pre Close460.75KTurnover22.23%Turnover RatioLossP/E (Static)8.51MShares4.089952wk High1.25P/B2.08MFloat Cap0.230052wk Low--Dividend TTM8.48MShs Float778.0000Historical High--Div YieldTTM12.36%Amplitude0.2300Historical Low0.2440Avg Price1Lot Size
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Genprex Stock Forum
Genprex's announcement represents positive early-stage validation for its lead candidate Reqorsa in a tough-to-treat subset of non-small cell lung cancer. The preclinical data specifically addresses KRASG12C mutant NSCLC with acquired resistance to sotorasib (Lumakras), highlighting a significant unmet need in lung cancer treatment.
The data demonstrates Reqorsa's multifaceted mechanism as a TUSC2 gene therapy - inhibiting critical signaling pathways (MAPK and...
Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer in Latest Study
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Wednesday, 26th March at 8:15 am
Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer
AUSTIN, Texas, March 26, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changi...
Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients
PR Newswire· 4 mins ago
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes
AUSTIN, Texas, March 25, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabete...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
No comment yet